MEDI-557

DRUG3 trials

Sponsors

MedImmune LLC

Conditions

HealthyRSV InfectionRespiratory Syncytial Virus

Phase 1

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

CompletedNCT00578682

MedImmune LLCHealthy

Start: 2007-12-31End: 2010-11-30Updated: 2011-11-23

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

TerminatedNCT01475305

MedImmune LLCRSV Infection

Start: 2011-10-20End: 2012-12-13Updated: 2017-07-21

MEDI-557 Adult Dosing

CompletedNCT01562938

MedImmune LLCRespiratory Syncytial Virus

Start: 2012-03-31End: 2013-07-31Updated: 2013-10-07

Related Papers

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Antimicrobial Agents and Chemotherapy2013-10-01343 citations